Leland Stanford Junior University

Hudsonalpha Institute for Biotechnology

Other

The Uab Research Foundation

The Board of Trustees of the Leland

Richard M Myers

Stanley Watson

Huda Akil

Edward G Jones

Jun Li

Prabhakara V Choudary

James Duane Brooks

Brian Scott Roberts

Hiroaki Tomita

Marquis P Vawter

Juan F Lopez

Robert C Thompson

Simon J Evans

Marie K Kirby

Alan F Schatzberg

William E Bunney

David R Cox

Donald J Buchsbaum

Albert De La Chapelle

Richard A Stein

Albert F LoBuglio

Len A Pennacchio

Cortney Turner

Margherita Molnar

Andres Forero-Torres

Jason Gertz

Anna-Elina Lehesjoki

Katherine E Varley

David M Lyons

Brandi Rollins

Kathleen Casey

William Byerley

William E Bunney, Jr

Mary Atz

William E Bunny

Margit Burmeister

William E Bunney Jr

Devin Absher

René Bernard

David Michael Lyons

Cortney A Turner

Michael Boehnke

Laura J Scott

Fan Meng

Ilan Kerman

Rene Bernard

The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.

Method of treating breast cancer

A method of reducing the abundance of a non-target micro-RNA (miRNA) that is part of a group of miRNAs is provided, including: (a) annealing a complementary region of a blocking nucleic acid to a binding site at a first end of the unwanted miRNA, ligating an adenylated nucleic acid adapter to the group of miRNAs, and performing RT-PCR on group of miRNAs. Kits and compounds for use with the method are also provided.

Method for blocking miRNA

The present disclosure provides for and relates to the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.

Differential methylation level of CpG loci that are determinative of a biochemical reoccurrence of prostate cancer

The present disclosure provides for and relates to cancer treatment based on the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.

Method of treating prostate cancer

A leaking tank testing device, including a main body, a tubing system disposed within at least a portion of the main body to receive contents therein from a tank container, a selector rotatably disposed on an outer surface of the main body to select a vacuum testing mode in a first position, and a pressure testing mode in a second position, a vacuum monitor disposed on at least a portion of the main body to display a gradient in pressure between the contents in the tubing system and an external pressure outside of the main body in response to the selector being moved to the vacuum testing mode, and a seal disposed on at least a portion of the main body to cover at least a portion of the tubing system in response to the selector being moved to the pressure testing mode.

Leaking tank testing device

Differential methylation level of CPG loci that are determinative of a biochemical reoccurrence of prostate cancer

A blocking nucleic acid for use in reducing the abundance of a non-target micro-RNA (miRNA) in an miRNA library is provided, including: a single-stranded complementary region at one of the 5' end of the blocking nucleic acid or the 3&#x2032; end of the blocking nucleic acid, that anneals with a binding region at a first end of the unwanted miRNA; a hairpin loop forming region or other double-stranded region adjacent to the complimentary region, in which all of the terminal ends of the blocking nucleic acid except one are unavailable to participate in ligase reactions. Methods and kits for using the blocking nucleic acid are also provided.

Described herein is an oil extraction device comprising a housing; a first trough resting within an upper portion of said housing, where said first trough holds a solvent; a heat source within said housing, where said heat source heats said first trough; a control device mounted within said housing, where said control device controls said heat source; a reservoir attached to said upper portion of said housing; a strainer basket positioned within said reservoir, where said strainer basket holds an extraction substance; a filter fitted within said strainer basket below said extraction substance; a second filter positioned above said extraction substance; a condenser positioned above said housing; a second trough positioned at a bottom portion of said condenser; and a set of flanges extruding from said condenser, where said set of flanges enable said condenser to cool and condense solvent vapor when operating said oil extraction device.

Oil extraction device for use at home and method of use

The present application relates to the treatment and diagnosis of mood disorders, including bipolar disorder, major depression disorder and schizophrenia. The invention provides novel diagnostic markers and assays, as well as research tools for the development and discovery of agents and compounds which are useful for treating patients who suffer from mental illness.

Methods for treating depression using NCAM peptide mimetics

The present invention provides methods for diagnosing mental disorders. The invention also provides methods of identifying modulators of mental disorders as well as methods of using these modulators to treat patients suffering from mental disorders.

Administration of FGF2 for treamtent of anxiety

The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia and mood disorders such as major depression disorder and bipolar disorder). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.

Compositions and methods for diagnosing and treating neuropsychiatric disorders

The present invention provides methods for diagnosing mental disorders such as mood disorders, including bipolar disorder I and II and major depression. The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.

Compositions and methods for diagnosing and treating mood disorders

Cystatin B mutants

Growing community of inventors

Stanford, CA, United States of America

Richard M Myers